GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OBI Pharma Inc (ROCO:4174) » Definitions » Notes Receivable

OBI Pharma (ROCO:4174) Notes Receivable : NT$0.00 Mil (As of Mar. 2025)


View and export this data going back to 2015. Start your Free Trial

What is OBI Pharma Notes Receivable?

OBI Pharma's Notes Receivable for the quarter that ended in Mar. 2025 was NT$0.00 Mil.


OBI Pharma Notes Receivable Historical Data

The historical data trend for OBI Pharma's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OBI Pharma Notes Receivable Chart

OBI Pharma Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

OBI Pharma Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

OBI Pharma Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


OBI Pharma Notes Receivable Related Terms

Thank you for viewing the detailed overview of OBI Pharma's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


OBI Pharma Business Description

Traded in Other Exchanges
N/A
Address
Zhongxiao E Road, 6th Floor, No. 508, Section 7, Nangang District, Taipei, TWN, 115
OBI Pharma Inc is engaged in new drugs research of novel cancer therapeutic agents for patients with unmet medical needs. The company has four reportable segments, which are anti-cancer new drug segment, bispecific monoclonal antibody new drug segment, botulinum toxin new drug segment and CDMO segment.

OBI Pharma Headlines

No Headlines